dc.contributor.author | Urvay S.E. | |
dc.contributor.author | Yucel B. | |
dc.contributor.author | Erdis E. | |
dc.contributor.author | Turan N. | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:31:40Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:31:40Z | |
dc.date.issued | 2016 | |
dc.identifier.issn | 1513-7368 | |
dc.identifier.uri | https://dx.doi.org/10.7314/APJCP.2016.17.10.4693 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/5310 | |
dc.description | Asian Pacific Organization for Cancer Prevention | en_US |
dc.description.abstract | Aim: The objective of this study is to investigate prognostic factors affecting survival of patients undergoing concurrent or sequential chemoradiotherapy (CRT) for stage III non-small-cell lung cancer (NSCL). Methods and materials: We retrospectively reviewed the clinical records of 148 patients with advanced, inoperable stage III NSCLC, who were treated between 2007 and 2015. Results: The median survival was found to be 19 months and 3-year overall survival was 27%. Age ( < 65 vs ?65 years, p=0.026), stage (IIIA vs IIIB, p=0.033), dose of radiotherapy (RT) ( < 60 vs ?60 Gy, p=0.024) and treatment method (sequential chemotherapy+RT vs concurrent CRT , p=0.023) were found to be factors affecting survival in univariate analyses. Gender, histological subtype, weight loss during CRT, performance status, induction/consolidation chemotherapy and presence of comorbidities did not affect survival (p > 0.050). Conclusion: Young age, stage IIIA, radiotherapy dose and concurrent chemoradiotherapy may positively affect survival in stage III NSCL cases. | en_US |
dc.description.sponsorship | Urvay, S.E.; Acibadem Hospitals Group, Birsen Y?celTurkey; email: semiha.urvay@acibadem.gov.tr | en_US |
dc.language.iso | eng | en_US |
dc.relation.isversionof | 10.7314/APJCP.2016.17.10.4693 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Non-small lung cancer | en_US |
dc.subject | Prognostic factors | en_US |
dc.subject | Survival | en_US |
dc.title | Prognostic factors in stage III non-small-cell lung cancer patients | en_US |
dc.type | article | en_US |
dc.relation.journal | Asian Pacific Journal of Cancer Prevention | en_US |
dc.contributor.department | Urvay, S.E., Acibadem Hospitals Group, Birsen Y?cel, Kayseri, Turkey -- Yucel, B., Cumhuriyet Univercity Medical Oncology Deparment, Sivas, Turkey -- Erdis, E., Cumhuriyet Univercity Medical Oncology Deparment, Sivas, Turkey -- Turan, N., Cumhuriyet Univercity Medical Oncology Deparment, Sivas, Turkey | en_US |
dc.identifier.volume | 17 | en_US |
dc.identifier.issue | 10 | en_US |
dc.identifier.endpage | 4697 | en_US |
dc.identifier.startpage | 4693 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |